Evolent Health, Inc. (EVH) - Dilution Analysis

10-Q filing | 115.3M shares outstanding

10-K filing | 114.7M shares outstanding

10-Q filing | 114.9M shares outstanding

10-Q filing | 114.7M shares outstanding

10-Q filing | 114.1M shares outstanding

10-K filing | 111.3M shares outstanding

8-K filing: Evolent Health, Inc. issued $402.5 million aggregate principal amount of 3.50% convertible senior notes due 2029 in a private placement, resulting in net proceeds of approximately $390.2 million. The notes are initially convertible into 10,590,782 shares of the Company's Class A common stock at an initial conversion price of approximately $38.00 per share.

8-K filing: Evolent Health, Inc. filed prospectus supplements related to the resale of shares of Class A common stock and shares issuable upon conversion of Series A Preferred Stock, both in connection with the NIA Acquisition.

10-Q filing | 112.3M shares outstanding

10-Q filing | 111.3M shares outstanding

10-Q filing | 107.8M shares outstanding

10-K filing | 111.1M shares outstanding

8-K filing: Evolent Health, Inc. will acquire National Imaging Associates, Inc. and certain assets of Magellan Specialty Health Division for $650 million, with a portion potentially paid in Class A shares. Additionally, Ares has committed to purchase $175 million of convertible preferred stock from EVH, Inc. to fund the transaction. ($250.0M proceeds)

10-Q filing | 99.3M shares outstanding

8-K filing: Evolent Health, Inc. consummated the exchange of $92.8 million in aggregate principal amount of 3.50% Convertible Senior Notes due 2024 for 5,394,165 shares of Class A common stock on August 17 and 18, 2022.

8-K filing: Evolent Health, Inc. entered into exchange agreements with certain noteholders to exchange $90.3 million in aggregate principal amount of 2024 Notes for approximately 5.2 million shares of Class A common stock, with the actual amount of shares not to exceed approximately 5.4 million shares, with closings expected to occur on or about August 17, 2022.

10-Q filing | 90.1M shares outstanding

8-K filing: Evolent Health, Inc. issued 3,741,731 shares of Class A Common Stock to equityholders of TPG Growth Iceman Parent in a private placement.

10-Q filing | 89.5M shares outstanding

10-K filing | 86.1M shares outstanding

10-Q filing | 85.8M shares outstanding

8-K filing: Evolent Health, Inc. issued 1,771,219 shares of Class A Common Stock to accredited investors as part of a merger agreement, exempt from registration under the Securities Act.

10-Q filing | 85.4M shares outstanding

8-K filing: Evolent Health, Inc. will issue 1,910,971 shares of Class A common stock as part of the Merger Consideration for the acquisition of Vital Decisions Acquisition, LLC, with potential for additional Class A Shares as Earnout Consideration. ($42.5M proceeds)

10-Q filing | 84.7M shares outstanding

10-K filing | 86.1M shares outstanding

10-Q filing | 85.8M shares outstanding

8-K filing: Evolent Health, Inc. completed exchange and subscription transactions involving its convertible senior notes, issuing new notes and repurchasing existing notes, and also amended its senior secured credit facility.

10-Q filing | 85.6M shares outstanding

10-Q filing | 84.6M shares outstanding

10-K filing | 79.2M shares outstanding

8-K filing: Evolent Health, Inc. entered into Warrant Agreements with Ares Capital Corporation and certain of its affiliates, issuing warrants to purchase up to 1,513,786 shares of the Company's Class A common stock at an exercise price of $8.05 per share.